how do we select the urothelial carcinoma patients who will benefit from checkpoint inhibitors?
Published 6 years ago • 69 plays • Length 0:57Download video MP4
Download video MP3
Similar videos
-
2:57
when can checkpoint inhibitors be used to treat urothelial carcinoma?
-
1:23
the role of immune checkpoint inhibitors in mcrpc
-
1:14
how can we continue the success of checkpoint inhibitors for bladder cancer treatment?
-
1:44
immune checkpoint inhibitors in mcrpc
-
1:56
immune checkpoint inhibitors for urothelial carcinoma: the current landscape
-
33:06
maximizing the of potential current and emerging immunotherapies in advanced endometrial cancer
-
44:56
immune checkpoint blockade in cancer therapy
-
15:51
introduction to immunotherapy (immunotherapy documentary part i)
-
4:11
what's next for checkpoint inhibitors in metastatic urothelial bladder cancer?
-
5:33
cancer immune checkpoint inhibitors
-
2:54
a 6-factor prognostic model for urothelial carcinoma patients receiving atezolizumab
-
1:29
will immune checkpoint inhibitors become the new standard of care for urothelial cancer?
-
10:44
earlier use of immune checkpoint inhibitors to adjuvant and non muscle invasive bladder cancer
-
4:43
impact of immune checkpoint inhibitors on care of patients with advanced bladder cancer
-
2:57
immune-checkpoint inhibitors for urothelial cancer
-
4:26
patient selection for checkpoint inhibitor therapy and assessing response
-
3:37
immune checkpoint inhibitor combinations: challenges and future perspectives
-
30:23
lecture looking ahead - potential barriers to immune checkpoint inhibitors use in mibc
-
14:42
managing toxicities associated with immune-checkpoint inhibitors
-
2:45
correlation between cutaneous immune-related adverse events and os with immune checkpoint inhibitors
-
29:57
immune checkpoint inhibitors with dr. kerry reynolds
-
4:00
overview of urothelial carcinoma treatment landscape – the promise of immunotherapy